- Reaction score
- 907
Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY1, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH.
Author information
Abstract
BACKGROUND:
Finasteride at a dose of 1 mg/d has been reported to show no significant improvement in 30-50% of patients with androgenetic alopecia (Androgenetic Alopecia). Dutasteride, a dual inhibitor of both type I and type II 5 alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, which is the key contributor of Androgenetic Alopecia.
MATERIALS AND METHODS:
Our aim is to evaluate clinical efficacy and tolerability of dutasteride in men with Androgenetic Alopecia who do not show clinical improvement to the conventional finasteride treatment. A total of 35 Korean men with Androgenetic Alopecia who had not shown significant clinical improvement when treated with finasteride 1 mg/d for at least six months received dutasteride at a dose of 0.5 mg/d for six months. Efficacy was evaluated by global photograph assessment and phototrichogram. Safety assessment was performed through physical examination and adverse event report.
RESULTS:
Of the 31 patients who completed the treatment, 24 patients (77.4%) were improved by the global photography (17 were slightly, six moderately, and one markedly improved) compared with the post-finasteride treatment. There was no significant change in seven patients (22.6%), and aggravation was not reported. Hair density and thickness significantly increased by 10.3% (87 ± 12-96 ± 12/cm(2)) and 18.9% (0.053 ± 0.012-0.063 ± 0.011 mm), respectively, in phototrichogram assessment. Side effects included transient sexual dysfunction in six patients (17.1%).
CONCLUSIONS:
Dutasteride is suggestive to be an alternative treatment option to patients with Androgenetic Alopecia who do not clinically respond to finasteride in six months.
© 2014 The International Society of Dermatology.
damn i want to try it , but still scared of the sides
Jung JY1, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH.
Author information
Abstract
BACKGROUND:
Finasteride at a dose of 1 mg/d has been reported to show no significant improvement in 30-50% of patients with androgenetic alopecia (Androgenetic Alopecia). Dutasteride, a dual inhibitor of both type I and type II 5 alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, which is the key contributor of Androgenetic Alopecia.
MATERIALS AND METHODS:
Our aim is to evaluate clinical efficacy and tolerability of dutasteride in men with Androgenetic Alopecia who do not show clinical improvement to the conventional finasteride treatment. A total of 35 Korean men with Androgenetic Alopecia who had not shown significant clinical improvement when treated with finasteride 1 mg/d for at least six months received dutasteride at a dose of 0.5 mg/d for six months. Efficacy was evaluated by global photograph assessment and phototrichogram. Safety assessment was performed through physical examination and adverse event report.
RESULTS:
Of the 31 patients who completed the treatment, 24 patients (77.4%) were improved by the global photography (17 were slightly, six moderately, and one markedly improved) compared with the post-finasteride treatment. There was no significant change in seven patients (22.6%), and aggravation was not reported. Hair density and thickness significantly increased by 10.3% (87 ± 12-96 ± 12/cm(2)) and 18.9% (0.053 ± 0.012-0.063 ± 0.011 mm), respectively, in phototrichogram assessment. Side effects included transient sexual dysfunction in six patients (17.1%).
CONCLUSIONS:
Dutasteride is suggestive to be an alternative treatment option to patients with Androgenetic Alopecia who do not clinically respond to finasteride in six months.
© 2014 The International Society of Dermatology.
damn i want to try it , but still scared of the sides